Oppenheimer & Co’s Grace Therapeutics GRCE Stock Holding History

Oppenheimer & Co’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.3K	Buy	+10,000	New	+$39.3K	﹤0.01%	1664
2021 Q1	–	Sell	-4,687	Closed	-$73K	–	1508
2020 Q4	$73K	Buy	4,687 +629	+16%	+$7.27K	﹤0.01%	1320
2020 Q3	$39K	Sell	4,058 -75	-2%	-$1.95K	﹤0.01%	1267
2020 Q2	$93K	Hold	4,133	–	–	﹤0.01%	1209
2020 Q1	$75K	Buy	4,133 +2,582	+166%	+$91.4K	﹤0.01%	1137
2019 Q4	$182K	Buy	1,551 +402	+35%	+$39.7K	﹤0.01%	1196
2019 Q3	$104K	Buy	+1,149	New	+$106K	﹤0.01%	1212

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Oppenheimer & Co's GRCE Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in Grace Therapeutics (GRCE) in Q1 2026: 10,000 shares worth $46.3K. The stake represents ﹤0.01% of the portfolio and ranks #1664 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in GRCE as recently as Q4 2020.

Oppenheimer & Co first reported a position in GRCE in Q3 2019 and has held it in 7 quarters since. The position peaked at $182K in Q4 2019. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

Oppenheimer & Co held 10,000 shares of Grace Therapeutics worth $46.3K as of Q1 2026.
Grace Therapeutics was a new Oppenheimer & Co position in Q1 2026.
Grace Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1664 holding.
Oppenheimer & Co first reported a position in Grace Therapeutics in Q3 2019 and has held it in 7 quarters since.
Oppenheimer & Co's Grace Therapeutics position peaked at $182K in Q4 2019.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.